Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3Completed 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Non-Hodgkin 11Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Pancreatic Neoplasms 1Neurologic Manifestations 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphatic Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1Brain Neoplasms 1

Interventions

Melphalan 16Cyclophosphamide 14Dexamethasone 13fludarabine phosphate 12Filgrastim 11Antilymphocyte Serum 11fludarabine 8Radiotherapy 8Mycophenolic Acid 8Cyclosporine 8Busulfan 8Whole-Body Irradiation 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Methylprednisolone 6Lenalidomide 6Bortezomib 6pomalidomide 5Rituximab 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Flow Cytometry 4Etoposide 4Arsenic Trioxide 4liposomal doxorubicin 3Thalidomide 3Surveys and Questionnaires 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Plasma Cell × Bendamustine Hydrochloride × Clear all
NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Columbia University

Phase 1/2 Terminated
23 enrolled 13 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

NYU Langone Health

Phase 2 Terminated
11 enrolled 9 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

NYU Langone Health

Phase 2 Terminated
24 enrolled 3 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡